CLAIM #2773 · AbbVie Inc (ABBV) · 2026Q1 earnings call · Apr 29, 2026 · due Dec 31, 2026
“I look forward to providing an additional dosing option for physicians and IBD patients later this year.”
Jeff Stewart · Chief Commercial Officer
PENDING
graded after results covering Dec 31, 2026 are reported
How to check this claim
Look at: Regulatory approval/launch of the additional dosing option (e.g., new dosing regimen/formulation) for the IBD product
It came true if: Company confirms approval and/or availability of the new dosing option before 2026-12-31
Where: Company press release, FDA approval announcement, or management commentary on quarterly earnings calls
Verify independently
SEC filings for ABBV ↗ · Claim quote is verbatim from the 2026Q1 earnings call.